NCT02798029
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Radiation therapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have 1-4 untreated metastatic brain lesions less than 5 cm in diameter
Exclusions: Patients with 5+ metastatic brain lesions; Patients with brain lesion(s) greater than 5 cm in diameter
https://ClinicalTrials.gov/show/NCT02798029